PMID- 25922725 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20150429 LR - 20220309 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 7 IP - 3 DP - 2015 Mar TI - Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. PG - 455-61 LID - 10.3978/j.issn.2072-1439.2015.02.06 [doi] AB - BACKGROUND: Currently, blockade of the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling pathway has been proved one of the most promising immunotherapeutic strategies against cancer. Several antibodies have been developed to either block the PD-1 or its ligand PD-L1 are under development. So far, a series of phase I trials on PD-1/PD-L1 antibodies for non-small cell lung cancer (NSCLC) have been completed, without reports of results from phase II studies. Thus, we sought to perform a meta-analysis incorporating all available evidences to evaluate the efficacy and safety of PD-1 or PD-L1 inhibition therapy. METHODS: Electronic databases were searched for eligible literatures. Data of objective respond rate (ORR) and rate of adverse effects (AEs) with 95% confidence interval (CI) evaluated by immunohistochemistry (IHC) was extracted. The outcomes were synthesized based on random-effect model. Subgroup analyses were proposed. RESULTS: In overall, ORR in the whole population with PD-1 blockage treatment is 22.5% (95% CI: 17.6% to 28.2%). Additionally, the rate of Grade 3-4 AEs is 16.7% (95% CI: 6.5% to 36.8%) and drug-related death rate is 2.5% (95% CI: 1.3% to 4.6%). As for patients with PD-L1 inhibition therapy, an overall ORR is 19.5% (95% CI: 13.2% to 27.7%). A higher rate of Grade 3-4 AEs (31.7%, 95% CI: 14.2% to 56.5%) is observed with a lower drug-related death rate (1.8%, 95% CI: 0.4% to 8.3%). In exploratory analyses of anti-PD-1 agents, we observed that greater ORR was presented in the median-dose cohort (3 mg/kg) than that of both low-dose (1 mg/kg) and high-dose (10 mg/kg) cohort (low-dose vs. median-dose: OR =0.12, P=0.0002; median-dose vs. high-dose: OR =1.47, P=0.18). CONCLUSIONS: Anti-PD-1 and anti PD-L1 antibodies showed objective responses in approximately one fourth NSCLC patients with a tolerable adverse-effect profile. In addition, median-dose (3 mg/kg) might be a preferential dosage of anti-PD-1 agents. FAU - Jia, Minghan AU - Jia M AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Feng, Weijiao AU - Feng W AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Kang, Shiyang AU - Kang S AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Zhang, Yaxiong AU - Zhang Y AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Shen, Jianfei AU - Shen J AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - He, Jiaxi AU - He J AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Jiang, Long AU - Jiang L AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Wang, Wei AU - Wang W AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Guo, Zhihua AU - Guo Z AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Peng, Guilin AU - Peng G AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Chen, Gang AU - Chen G AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - He, Jianxing AU - He J AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. FAU - Liang, Wenhua AU - Liang W AD - 1 Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China ; 3 Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. LA - eng PT - Journal Article PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC4387409 OTO - NOTNLM OT - Anti-programmed cell death-1 (anti-PD-1) OT - anti-programmed cell death-ligand 1 (anti-PD-L1) OT - non-small cell lung cancer (NSCLC) EDAT- 2015/04/30 06:00 MHDA- 2015/04/30 06:01 PMCR- 2015/03/01 CRDT- 2015/04/30 06:00 PHST- 2015/01/03 00:00 [received] PHST- 2015/01/29 00:00 [accepted] PHST- 2015/04/30 06:00 [entrez] PHST- 2015/04/30 06:00 [pubmed] PHST- 2015/04/30 06:01 [medline] PHST- 2015/03/01 00:00 [pmc-release] AID - jtd-07-03-455 [pii] AID - 10.3978/j.issn.2072-1439.2015.02.06 [doi] PST - ppublish SO - J Thorac Dis. 2015 Mar;7(3):455-61. doi: 10.3978/j.issn.2072-1439.2015.02.06.